ERBB2 and breast carcinoma: Both HER2 and integrin trafficking and recycling regulation may influence the invasive and metastatic potential of breast cancer cells co-expressing these proteins, and could have therapeutic consequences as recycling effects the amount of surface protein available for drug targeting.